Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

European Journal of Cancer

Volumn 39, Issue 7, 2003, Pages 917-926

  Eskens, F A L M ^a   Dumez, H ^b   Hoekstra, R ^a   Perschl, A ^c   Brindley, C ^d   Bottcher S ^c   Wynendaele, W ^b   Drevs, J ^e   Verweij, J ^a   Van Oosterom, A T ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MERCK KGAA   (Germany)

^d IQVIA   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiogenesis inhibitor; Cilengitide (EMD 121974); Integrins; Pharmacology; Phase I clinical trial

Indexed keywords

CILENGITIDE; INTEGRIN; INTEGRIN ALPHA V BETA 3; INTEGRIN ALPHA V BETA 5; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TOXICITY;

EID: 0347155579     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00057-1     Document Type: Article

References (24)

1. Cherish D. Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and Van Willebrand factor. Proc Natl Acad Sci USA. 84:1987;6471-6475.
2. Cheresh D. Integrins. structure, function and biological properties Adv Mol Cell Biol. 6:1993;225-252.
3. Varner J.A., Brooks P.C., Cheresh D.A. Review. the integrin αvβ3: angiogenesis and apoptosis Cell Adhes Comm. 3:1995;367-374.
4. Max R., Gerritsen R.R.C.M., Nooijen P.T.G.A.et al. Immunohistochemical analysis of integrin αvβ3 expression on tumour-associated vessels of human carcinomas. Int J Cancer. 71:1997;320-324.
5. Brooks P.C., Clarke R.A.F., Cheresh D.A. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 264:1994;569-571.
6. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., Cheresh D.A. Definition of two angiogenic pathways by distinct αv integrins. Science. 270:1995;1500-1502.
7. Li X., Chen B., Blystone S.D., McHugh K.P., Ross F.P., Ramos D.M. Differential expression of αv integrins in K1735 melanoma cells. Invasion Metastasis. 18:1998;1-14.
8. Friedlander M., Theesfeld C.L., Sugita M.et al. Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 93:1996;9764-9769.
9. Gasparini G., Brooks P.C., Biganzoli E.et al. Vascular integrin αvβ3. a new prognostic indicator in breast cancer Clin Cancer Res. 4:1998;2625-2634.
10. Guidelines for Reporting of Adverse Drug Reactions. 1988;Division of cancer treatment, National Cancer Institute, Bethesda.
11. WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 40. 1979;WHO, Geneva, Switzerland.
12. Gough K., Hutchison M., Keene O. Assessment of dose proportionality. report from the statisticians in the pharmaceutical industry/Pharmacokinetics UK joint working party Drug Inform J. 29:1995;1039-1048.
13. Peters K.G., Coogan A., Berry D.et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer. 77:1998;51-56.
14. Hayes A.J., Huang W.Q., Mallah J., Yang D., Lippman M.E., Li L.Y. Angiopoeitin-1 and its receptor Tie-2 participate in the regulation of capillary-like tube formation and survival of endothelial cells. Microvasc Res. 58:1999;224-237.
15. Hebbar M., Revillion F., Louchez M.M., Fournier C., Bonneterre J., Peyrat J.P. Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients. Clin Cancer Res. 5:1999;1427-1433.
16. Wynendaele W., Derua R., Hoylaerts M.F.et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers. a key to study an angiogenic marker in vivo? Ann Oncol. 10:1999;965-971.
17. Barleon B., Siemeister G., Martiny-Baron G., Weindel K., Herzog C., Marme D. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase (FLT-1) and a soluble form of FLT-1 in human vascular endothelial cells. Cancer Res. 57:1997;5421-5425.
18. Cutler N.R., Sramek J.J., Greenblatt D.J., Chaikin P., Collins J. Defining the maximum tolerated dose. an update J Clin Pharmacol. 40:2000;1183-1204.
19. Arbuck S.G. Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol. 7:1996;567-573.
20. Gutheil J.C., Campbell T.N., Pierce P.R.et al. Targeted antiangiogenic therapy for cancer using Vitaxin. a humanized monoclonal antibody to the integrin αvβ3 Clin Cancer Res. 6:2000;3056-3061.
21. Eskens F.A.L.M., Verweij J. Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models. facing the challenge of a proper study design Crit Rev Oncol Hematol. 34:2000;83-88.
22. Gelmon K.A., Eisenhauer E.A., Harris A.L., Ratain M.J., Workman P. Anticancer agents targeting signaling molecules and cancer cell environment. challenges for drug development? J Natl Cancer Inst. 91:1999;1281-1287.
23. Gordon M.S., Margolin K., Talpaz M.et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 19:2001;843-850.
24. Margolin K., Gordon M.S., Holmgren E.et al. Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer. pharmacologic and long-term safety data J Clin Oncol. 19:2001;851-856.